Aquestive Therapeutics

AQST

Market cap $611M

Overview Fund Activity

5.05 USD

+0.10

2.02%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

5.13

+0.08

1.58%

1 day

2.02%

5 days

-8.18%

1 month

33.6%

3 months

52.57%

6 months

71.77%

Year to date

37.6%

1 year

10.99%

5 years

-41.35%

10 years

-68.54%

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Employees: 142

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

104% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 26

21% more capital invested

Capital invested by funds: $131M [Q1] → $158M (+$26.9M) [Q2]

3.18% more ownership

Funds ownership: 44.76% [Q1] → 47.93% (+3.18%) [Q2]

5% less funds holding

Funds holding: 121 [Q1] → 115 (-6) [Q2]

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

38% less call options, than puts

Call options by funds: $729K | Put options by funds: $1.17M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

58% upside

Avg. target

$9

78% upside

High target

$10

98% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Francois Brisebois	$8	Outperform Maintained	8 Sep 2025
HC Wainwright & Co. Raghuram Selvaraju	$10	Buy Reiterated	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an advisory committee is a positive signal, and clinical data seems to strongly support Anaphylm's safety and efficacy. If approved, Anaphylm could capture significant market share, potentially driving Aquestive's valuation above $1bn and offering >50% upside for investors.

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

Zacks Investment Research

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Zacks Investment Research

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and for working capital, capital expenditures and general corporate purposes. All of the securities are to be sold by the Company. The offering is expected to close on or about August 15, 2025, subject to satisfaction of customary closing conditions.

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP (“RTW”), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions.

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants A. Ernest Toth - Chief Financial Officer Carl N.

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update.

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the promotion of Sherry Korczynski, from Senior Vice President of Sales and Marketing, to Chief Commercial Officer effective July 22, 2025.

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

See News Rankings

Charts implemented using Lightweight Charts™